SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-063274
Filing Date
2023-11-14
Accepted
2023-11-13 20:41:29
Documents
72
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acor-20230930.htm   iXBRL 10-Q 2061929
2 EX-31.1 acor-ex31_1.htm EX-31.1 12250
3 EX-31.2 acor-ex31_2.htm EX-31.2 11261
4 EX-32.1 acor-ex32_1.htm EX-32.1 6962
5 EX-32.2 acor-ex32_2.htm EX-32.2 7057
  Complete submission text file 0000950170-23-063274.txt   9204396

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT acor-20230930_def.xml EX-101.DEF 251505
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acor-20230930_pre.xml EX-101.PRE 405478
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acor-20230930.xsd EX-101.SCH 63483
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acor-20230930_lab.xml EX-101.LAB 549396
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT acor-20230930_cal.xml EX-101.CAL 54848
66 EXTRACTED XBRL INSTANCE DOCUMENT acor-20230930_htm.xml XML 1755566
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

IRS No.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-31938 | Film No.: 231401103
SIC: 2836 Biological Products, (No Diagnostic Substances)